Partial
Partially Aligned
Patient Risk:
Low
Summary
The response includes several accurate, label-supported clinical/description and dosing-related claims, but also contains multiple non-label claims about cost, manufacturer/assistance programs, discount cards, and patent resources, plus an overbroad cancer-treatment indication statement beyond the specific label indications provided.
Category Scores
Accurate Statements
Prolia is administered 60 mg subcutaneously once every 6 months.
Section 2.3 Recommended Dosage
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Section 1.1
Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture.
Section 1.2
Denosumab is a human IgG2 monoclonal antibody with affinity for human RANKL.
Section 11 Description
Prolia binds RANKL and prevents RANKL/RANK interaction, decreasing bone resorption by inhibiting osteoclast formation, function, and survival.
Section 12.1 Mechanism of Action
Unsupported Statements
Prolia (denosumab) is a high-cost medication.
No support in the provided label sections.
Without insurance coverage, a single injection of Prolia can range from approximately $700 to over $1,000.
No support in the provided label sections.
The cost described covers one 60 mg dose of Prolia.
Label supports the dose (60 mg) but does not support the stated cost range.
Patients without insurance may be eligible for patient assistance programs offered by the manufacturer, Amgen.
No support in the provided label sections.
Patient assistance programs can provide Prolia at a reduced cost or for free to eligible individuals based on income and insurance status.
No support in the provided label sections.
Some pharmacies may offer discount cards or programs that can lower out-of-pocket expenses for Prolia.
No support in the provided label sections.
Amgen manufactures Prolia.
No support in the provided label sections.
Amgen is responsible for the development, production, and marketing of Prolia.
No support in the provided label sections.
Information regarding Prolia's patent status and potential patent expiry dates is available on resources like DrugPatentWatch.com.
No support in the provided label sections.
Contradictions
Low
AI Statement
None identified as directly conflicting with the provided FDA label excerpts.
Label Reference
N/A
Important Omissions
Label-required safety content was not addressed (e.g., contraindications, boxed warnings if any, and warnings/precautions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The non-label claims evaluated relate primarily to cost/access information and do not include dosing modification, contraindications, or dosing-safety assertions in the provided excerpts. No direct contradictions to the provided label were identified; however, multiple unsupported claims could mislead readers about access/purchasing and the cancer-treatment scope was broader than the specific label indications.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several statements are absent from the FDA label excerpts (cost, manufacturer responsibility, assistance/discount programs, and patent-resource claims). One cancer-related indication statement is overly broad relative to the specific labeled cancer-related populations provided.
Suggested Improvement
Remove or clearly label as non-FDA-label information any cost, discount program, manufacturer responsibility, and patent-resource claims unless supported by the provided prescribing information. Constrain cancer-related indications to the specific labeled populations (ADT for nonmetastatic prostate cancer; adjuvant aromatase inhibitor therapy for breast cancer).